Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
23.30
-0.28 (-1.19%)
Jan 31, 2025, 4:00 PM EST - Market closed
Denali Therapeutics Revenue
In the year 2023, Denali Therapeutics had annual revenue of $330.53M with 204.74% growth.
Revenue (ttm)
$330.53M
Revenue Growth
+204.74%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
445
Market Cap
3.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | 335.66M | 308.98M | 1,158.19% |
| Dec 31, 2019 | 26.68M | -102.48M | -79.35% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
DNLI News
- 17 days ago - Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga
- 23 days ago - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains - Seeking Alpha
- 26 days ago - Denali Therapeutics ALS drug fails in mid-stage trial - Reuters
- 26 days ago - Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire
- 4 weeks ago - Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga
- 2 months ago - Denali Has A Neurodegenerative Edge Despite Market Skepticism - Seeking Alpha
- 3 months ago - Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) - GlobeNewsWire